Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [18] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [19] - Adjusted EPS for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [18] - Full year 2025 adjusted EPS was $3.06, growing 22% versus 2024, also exceeding guidance [19] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [4] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [4] - Neuromodulation grew 10% in Q4 and delivered 8% organic growth for the full year, with strong performance from the brain franchise [5] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [6] - Watchman business grew 29% in Q4 and maintained strong double-digit growth for the full year [12] Market Data and Key Metrics Changes - U.S. operational growth was 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [2] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [3] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [2] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [3] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth markets and expanding product offerings [24][6] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key segments [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27] - The company expects to face challenges in the first half of 2026 due to product removals and market adjustments but anticipates stronger performance in the latter half [25][43] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive long-term growth [61] Other Important Information - The company reported free cash flow of $3,659 million for the full year 2025, exceeding expectations [22] - The legal reserve was $242 million as of December 31, with $46 million already funded [24] - The company maintains a strong balance sheet with cash on hand of $1.965 billion and a gross debt leverage ratio of 1.9 times [23] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management reassured that Q4 results exceeded internal targets, with EP growing 35% and Watchman growing 29%, indicating strong market share gains [30][34] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [36][38] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [41][42] Question: Diversification of growth drivers - Management highlighted strong performance expected in Neuromod, Urology, and Endoscopy, with ongoing investments to ensure consistent growth across all business units [59][60]

Core Viewpoint - Boston Scientific reported quarterly earnings of $0.8 per share, exceeding the Zacks Consensus Estimate of $0.78 per share, and showing an increase from $0.7 per share a year ago, indicating a positive earnings surprise of +2.96% [1] Financial Performance - The company achieved revenues of $5.29 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.39%, and up from $4.56 billion year-over-year [2] - Over the last four quarters, Boston Scientific has consistently exceeded consensus EPS estimates and revenue estimates [2] Stock Performance - Boston Scientific shares have declined approximately 3.9% since the beginning of the year, while the S&P 500 has gained 1.1% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.79, with expected revenues of $5.2 billion, and for the current fiscal year, the EPS estimate is $3.45 on revenues of $22.32 billion [7] - The estimate revisions trend for Boston Scientific was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Boston Scientific belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Boston Scientific's stock may be influenced by the overall outlook for the industry [8]

The medical-device maker beats quarterly earnings expectations but offers a disappointing outlook for the current quarter. ...

Q4 2025 Highlights February 4, 2026 1 Q4 2025 Financial & Operational Highlights | February 4, 2026 Forward-Looking Statements and Use of Document Forward-looking statements: FCF is a non-GAAP measure calculated as operating cash flows less net purchases of property, plant, and equipment and internal use software. FCF Conversion is a non-GAAP measure calculated as FCF divided by adjusted net income available to common stockholders. Emerging Markets: Our Emerging Markets countries include all countries excep ...

Core Insights - Boston Scientific has reported strong growth in its electrophysiology sales, particularly in the pulsed field ablation (PFA) market, positioning itself as a market leader [1][2]. Financial Performance - Q4 sales reached $5.29 billion, marking a nearly 16% increase year over year [1]. - Electrophysiology sales for Q4 totaled $890 million, reflecting a 37% year-over-year growth [1][3]. - Projected sales for 2025 are $20.07 billion, indicating a nearly 20% increase year over year [1]. - Electrophysiology sales for 2025 are expected to reach $3.33 billion, showing a significant 74.6% growth year over year [1]. Market Dynamics - Despite strong overall performance, U.S. sales growth for the electrophysiology unit stalled in Q4 compared to Q3, raising concerns among analysts [2][3]. - CEO Mike Mahoney expressed confidence in the PFA market's potential, anticipating a growth rate of about 15% in 2026, with expectations for the company to exceed this rate [2]. - The slowdown in growth may be attributed to increased market penetration and a shift in treatment approaches for atrial fibrillation, with approximately 70% of ablation procedures in the U.S. utilizing PFA in 2025 [6]. Investor Sentiment - Analysts have expressed concerns regarding the trajectory of key growth drivers, particularly after the flat U.S. sales performance in Q4, leading to a nearly 16% drop in the company's stock price [4]. - The company experienced a notable slowdown in electrophysiology growth, with previous quarters showing much higher growth rates, such as 143% in Q1 2025 and 96% in Q2 2025 [5].

FOR IMMEDIATE RELEASE Boston Scientific announces results for fourth quarter and full year 2025 Marlborough, Mass. (February 4, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational basis and 12.7 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 milli ...

123 MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational basis and 12.7 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, ...

Boston Scientific Corporation (NYSE:BSX) will release earnings for its fourth quarter before the opening bell on Wednesday, Feb. 4.Analysts expect the Marlborough, Massachusetts-based company to report quarterly earnings of 78 cents per share. That's up from 70 cents per share in the year-ago period. The consensus estimate for Boston Scientific's quarterly revenue is $5.28 billion (it reported $4.56 billion last year), according to Benzinga Pro.The U.S. Food and Drug Administration (FDA), last month, said i ...

Boston Scientific Corporation (NYSE:BSX) will release earnings for its fourth quarter before the opening bell on Wednesday, Feb. 4.Analysts expect the Marlborough, Massachusetts-based company to report quarterly earnings of 78 cents per share. That's up from 70 cents per share in the year-ago period. The consensus estimate for Boston Scientific's quarterly revenue is $5.28 billion (it reported $4.56 billion last year), according to Benzinga Pro.The U.S. Food and Drug Administration (FDA), last month, said i ...

Core Viewpoint - Analysts forecast that Boston Scientific (BSX) will report quarterly earnings of $0.78 per share, reflecting an 11.4% year-over-year increase, with revenues expected to reach $5.27 billion, a 15.4% increase compared to the previous year [1]. Earnings Estimates - Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter, indicating stability in analysts' forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong relationship between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts predict 'Net Sales- MedSurg- Worldwide' will reach $1.80 billion, indicating an 11.5% year-over-year change [5]. - The consensus estimate for 'Net Sales- Cardiovascular- Worldwide' stands at $3.46 billion, reflecting a 17.5% increase from the year-ago quarter [5]. - 'Net Sales- MedSurg- Urology- Worldwide' is expected to be $725.74 million, showing a 15.2% year-over-year change [5]. - 'Net Sales- MedSurg- Endoscopy- Worldwide' is forecasted to reach $756.05 million, indicating a 9.6% increase from the previous year [6]. - 'Geographic Revenue- Rest of the World' is projected to be $1.88 billion, reflecting a 12.4% year-over-year change [6]. - 'Geographic Revenue- U.S.' is expected to reach $3.39 billion, indicating a 17% increase [6]. - 'Net Sales- Cardiovascular- Peripheral Interventions- International' is estimated at $297.57 million, suggesting an 11% year-over-year change [7]. - 'Net Sales- MedSurg- Neuromodulation- United States' is projected to be $247.55 million, reflecting a 7.2% increase [7]. - 'Net Sales- MedSurg- Neuromodulation- International' is expected to be $75.13 million, indicating a 10.5% year-over-year change [8]. - 'Net Sales- MedSurg- Endoscopy- United States' is forecasted to reach $462.66 million, reflecting a 9.4% increase [8]. - 'Net Sales- MedSurg- Endoscopy- International' is projected at $293.49 million, indicating a 9.9% year-over-year change [9]. - 'Net Sales- MedSurg- Urology- United States' is expected to be $545.86 million, reflecting an 18.9% increase from the previous year [9]. Stock Performance - Over the past month, shares of Boston Scientific have returned -3.2%, while the Zacks S&P 500 composite has changed by +0.9% [9]. - Currently, BSX carries a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [9].